home / stock / iugnf / iugnf quote
Last: | $0.0525 |
---|---|
Change Percent: | 17.43% |
Open: | $0.045 |
Close: | $0.0525 |
High: | $0.0525 |
Low: | $0.045 |
Volume: | 6,225 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0525 | $0.045 | $0.0525 | $0.0525 | $0.045 | 6,225 | 05-06-2024 |
$0.0545 | $0.0493 | $0.0545 | $0.0558 | $0.048 | 65,359 | 05-03-2024 |
$0.054 | $0.0528 | $0.054 | $0.058 | $0.05 | 102,491 | 05-02-2024 |
$0.0525 | $0.0525 | $0.0525 | $0.0525 | $0.05 | 21,700 | 05-01-2024 |
$0.0525 | $0.0525 | $0.0525 | $0.0525 | $0.0525 | 17,600 | 04-30-2024 |
$0.053 | $0.053 | $0.053 | $0.053 | $0.053 | 5,050 | 04-29-2024 |
$0.051 | $0.0485 | $0.051 | $0.055 | $0.0485 | 168,845 | 04-26-2024 |
$0.0528 | $0.0455 | $0.0528 | $0.0528 | $0.0455 | 15,286 | 04-25-2024 |
$0.0525 | $0.0525 | $0.0525 | $0.0525 | $0.0525 | 10,000 | 04-24-2024 |
$0.05 | $0.0552 | $0.05 | $0.0565 | $0.05 | 35,500 | 04-23-2024 |
$0.058 | $0.0572 | $0.058 | $0.065 | $0.0432 | 342,166 | 04-22-2024 |
$0.05 | $0.052 | $0.05 | $0.052 | $0.05 | 1,034,573 | 04-19-2024 |
$0.055 | $0.0568 | $0.055 | $0.057 | $0.055 | 54,987 | 04-18-2024 |
$0.0558 | $0.058 | $0.0558 | $0.058 | $0.0472 | 46,900 | 04-17-2024 |
$0.058 | $0.058 | $0.058 | $0.058 | $0.056 | 197,510 | 04-16-2024 |
$0.0601 | $0.06 | $0.0601 | $0.0625 | $0.06 | 141,150 | 04-15-2024 |
$0.0615 | $0.063 | $0.0615 | $0.063 | $0.0538 | 138,000 | 04-12-2024 |
$0.0645 | $0.064 | $0.0645 | $0.0645 | $0.064 | 31,324 | 04-11-2024 |
$0.0675 | $0.07 | $0.0675 | $0.07 | $0.0675 | 55,535 | 04-10-2024 |
$0.0675 | $0.0675 | $0.0675 | $0.0675 | $0.0675 | 10,000 | 04-09-2024 |
News, Short Squeeze, Breakout and More Instantly...
Imugene Ltd Company Name:
IUGNF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss the strategic partnership the company has formed with Kincell Bio, LLC that involves the sale of Imugene's Current Good Manufacturing Practice (CGMP) complia...
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieve...
(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss enrolment for a pivotal expansion study targeting bile tract cancer (cholangiocarcinoma) patients. This follows the successful completion of the fifth high-dose cohort in the intr...